Evidence map›Paper›PMID 42015253›Full record

ArticleNeurological research and practice2026

The best treatment is prevention: prevention of cognitive decline and dementia - current state, gaps and next steps.

Kathrin Reetz, Inga Liepelt-Scarfone, Alexa Häger, Agnes Flöel, Jörg B Schulz, Dementia Commission of the German Society for Neurology (DGN)

Abstract read
In one paragraph

Article in Neurological research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kathrin ReetzDepartment of Neurology, Centre for Dementia and Prevention Aachen (ZDPA), RTWH Aachen University, Aachen, Germany. kreetz@ukaachen.de.ORCID http://orcid.org/0000-0002-9730-9228
Inga Liepelt-ScarfoneHertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases (DZNE), University of Tubingen, Tubingen, Germany.
Alexa HägerDepartment of Neurology, Centre for Dementia and Prevention Aachen (ZDPA), RTWH Aachen University, Aachen, Germany.
Agnes FlöelDepartment of Neurology, University Medicine, 17475, Greifswald, Germany.
Jörg B SchulzDepartment of Neurology, Centre for Dementia and Prevention Aachen (ZDPA), RTWH Aachen University, Aachen, Germany.
Dementia Commission of the German Society for Neurology (DGN)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization (WHO) recognises dementia as a public health priority. Currently, more than 55 million people live with dementia, and this figure is expected to almost triple to 139 million by 2050. Alzheimer’s disease is the most common cause of dementia, and there is still no cure. Despite the availability of symptomatic and first disease-modifying treatments, effective treatment remains limited. This makes it even more important to be aware that it is estimated that nearly half of all dementia cases could be prevented by eliminating 14 major risk factors. Consequently, the role of these modifiable risk factors has been the subject of research to inform effective preventive strategies. This narrative review summarises the current evidence on the prevention of cognitive decline and dementia. First, we provide an overview of the current state on risk factors, multimodal clinical controlled trials for slowing down or preventing dementia and primordial, primary, secondary, tertiary and quaternary prevention of cognitive decline and dementia. Second, we evaluate knowledge and action gaps in the field. Finally, we discuss how to address these gaps and what the next steps should be. Overall, to accelerate progress, the following key calls to action are paramount: (1) making prevention of cognitive decline and dementia a priority; (2) promoting brain health throughout the lifespan through coordinated intersectoral action targeting key risk factors; (3) improving access to diagnosis and treatment for patients with cognitive decline and dementia; and (4) encouraging research on prevention and how to translate knowledge into action.

Indexed as

Alzheimer’s diseaseCognitive declineDementiaEducationPreventionPublic healthRisk factorsTreatment

Identifiers

PMID42015253
PMCPMC13101104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.